Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392892 | 0.90 | KMT2A (0.33) | PSMB8PSMB5 | |
| SCHEMBL43720 | 0.90 | TSHR (0.34) | PSMB8PSMB5LMNA | |
| SCHEMBL5029861 | 0.86 | PSMB8 (0.33) | PSMB8PSMB5LMNA | |
| SCHEMBL13698947 | 0.85 | SMN1; SMN2 (0.33) | PSMB8PSMB5 | |
| SCHEMBL768869 | 0.85 | TSHR (0.45) | PSMB8PSMB5LMNA | |
| SCHEMBL26199195 | 0.84 | — | — | |
| SCHEMBL27362202 | 0.83 | TSHR (0.30) | PSMB8PSMB5LMNA | |
| SCHEMBL15958386 | 0.83 | PSMB8 (0.31) | PSMB8PSMB5 | |
| SCHEMBL9285468 | 0.82 | ALDH1A1 (0.34) | PSMB8PSMB5LMNA | |
| SCHEMBL24533288 | 0.82 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289483-A2 | BIOMOLECULE CONJUGATES | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230190951-A1 | CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS | SYNAFFIX B.V. (NL) | 2023-06-22 | — | — | US | disclosed |
| US-20220168436-A1 | ANTIBODY DRUG CONJUGATES | PHARMA MAR SA (ES) | 2022-06-02 | — | — | US | disclosed |
| US-20220168436-A1 | ANTIBODY DRUG CONJUGATES | PHARMA MAR SA (ES) | 2022-06-02 | — | — | US | disclosed |
| US-11345715-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | REGENERON PHARMACEUTICALS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11224663-B2 | Antibody drug conjugates | PHARMA MAR, S.A. (ES) | 2022-01-18 | — | — | US | disclosed |
| US-11224663-B2 | Antibody drug conjugates | PHARMA MAR, S.A. (ES) | 2022-01-18 | — | — | US | disclosed |
| EP-3903826-A1 | BIOMOLECULE CONJUGATES | Celgene Corporation (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20200277306-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | REGENERON PHARMACEUTICALS, INC. | 2020-09-03 | — | — | US | disclosed |
| US-10570151-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | REGENERON PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-1913002-B1 | METHOD OF ACYLATING MAYTANSINOL WITH CHIRAL AMINO ACIDS | MILLENNIUM PHARM INC (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110280890-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8012978-B2 | Prodrugs of CC-A1065 analogs | IMMUNOGEN, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7598375-B2 | Method of acylating maytansinol with chiral amino acids | MILLENIUM PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090028821-A1 | PRODRUGS OF CC-A1065 ANALOGS | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
| EP-1913002-A2 | METHOD OF ACYLATING MAYTANSINOL WITH CHIRAL AMINO ACIDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007021674-A2 | METHOD OF ACYLATING MAYTANSINOL WITH CHIRAL AMINO ACIDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037972-A1 | For making maytansinoids with chiral amino acid side chains; maytansinoids may be conjugated to cell-binding agents such as antibodies and are useful therapeutics, especially for treatment of cancer; high yielding methods that avoid or reduce epimerization in coupling of side chain linker | MILLENNIUM PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |
| US-5395924-A | Oligosaccharide or glycopeptide bound to lectin and conjugated with cell binding agent, improved targeting of cells for cytolysis | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1995-03-07 | — | — | US | disclosed |
| US-5239062-A | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1993-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570151-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | CD47, CD44, ACP1 | PSMB8 2223/4885PSMB5 3662/4885LMNA 2108/4885 |
| US-20220168436-A1 | ANTIBODY DRUG CONJUGATES | CD79B, OGFR, CD2 | PSMB8 3154/4885PSMB5 2322/4885LMNA 1922/4885 |
| US-20110280890-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, SENP5, CWC15 | PSMB8 1786/4885PSMB5 147/4885LMNA 4728/4885 |
| US-11345715-B2 | Biologically active molecules, conjugates thereof, and therapeutic uses | CD47, CD44, ACP1 | PSMB8 2223/4885PSMB5 3662/4885LMNA 2108/4885 |
| US-20200277306-A1 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES | CD47, CD44, ACP1 | PSMB8 2223/4885PSMB5 3662/4885LMNA 2108/4885 |
| US-20070037972-A1 | For making maytansinoids with chiral amino acid side chains; maytansinoids may be conjugated to cell-binding agents such as antibodies and are useful therapeutics, especially for treatment of cancer; high yielding methods that avoid or reduce epimerization in coupling of side chain linker | MRTO4, SLC43A1, SLC7A1 | PSMB8 3760/4885PSMB5 2410/4885LMNA 3430/4885 |
| US-20230190951-A1 | CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS | FCGR3B, FCGR1A, FCGR2A | PSMB8 2404/4885PSMB5 1333/4885LMNA 4334/4885 |
| US-11224663-B2 | Antibody drug conjugates | CD79B, OGFR, CD22 | PSMB8 2935/4885PSMB5 1594/4885LMNA 2165/4885 |
| US-20090028821-A1 | PRODRUGS OF CC-A1065 ANALOGS | PDIA5, CA6, STS | PSMB8 1898/4885PSMB5 186/4885LMNA 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.